Here, I’m talking about the newest class of weight-loss drugs, the “GLP-1 drugs.” Indeed, the long-term impact of GLP-1 drugs has been a significant story in markets throughout 2023, but lately its had a bigger macro impact as expectations for this drug have resulted in substantial ...
Eithther the 22.7% or the 20.4% of patients’ body weight loss, on average, fell short of the 25% weight loss that Novo Nordisk projected previously for its next-generation drug. The company has predicted CagriSema will help patients lose “at least 25%” of their body weight. That wo...
10 Best Tech Stocks to Buy for 2025 Analysts are pounding the table on these tech stocks. Wayne DugganApril 22, 2025 5 Great Fixed-Income Funds to Buy Now Investors can disconnect from equity markets while still earning decent returns with these bond funds. ...
Novo Nordisk, which manufactures the fiercely popular weight-loss drug Wegovy,previously forecastweight loss of 25% for patients who take CagriSema. In another late-trial result published in December, the company found CagriSema helped patients reduce their weight by 22.7%. Read the full story her...
Analyst Sel Hardy says Lilly's growth drivers include the GLP-1 weight loss drug boom and an aging U.S. population. CFRA has a "buy" rating and $1,045 price target for LLY stock, which closed at $732.41 on April 11. Sponsored Brokers 1 Interactive Brokers Account Minimum $0 Fee $0...
In the US, the drug sells for as much as $1,350 (£1,070) a month. The NHS has also been urged to use virtual platforms to prescribe weight loss drugs in future. In draft guidelines, NICE recommended the use of four online platforms that allow specialists to provide ...
think about stocks for a volatile market, a stock likeCoca-Cola(NYSE:KO) comes to mind. KO stock is down more than 17% in 2023. That could be the result of normalized growth or concerns about valuation. There’s also growing distaste for “snack stocks” in the age of weight loss ...
Stocks NamePortfolio Weight (%)Market Value(USD) S&P 500 Index Swap130.33-198.74M Goldman Sachs FS Treasury Intms Instl88.58135.08M Goldman Sachs Fin Gov 465 Institut77.30117.87M Dreyfus Government Secs Cash Mgmt Admin52.52530.59M Dreyfus Government Secs Cash Mgmt Admin49.55511.86M ...
Eli Lilly's GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for weight loss), are far from the only growth drivers in its portfolio. Even as the regulatory and reimbursement landscape for GLP-1 drugs evolves, the company has a broad portfolio of other successful drugs in disease areas...
A concentrated portfolio of expensive stocks may be at risk of loss if those companies' earnings growth slows.The current turbulence in US stocks is providing investors with a reminder of why diversification is important for managing risk. As the S&P 500 was rising over the past 5 years, many...